These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 14663175

  • 1. Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment.
    Athanassiou-Metaxa M, Tzimouli V, Economou M, Taparkou A, Tourkantoni N, Kanakoudi-Tsakalidou F.
    Acta Haematol; 2003; 110(4):224-6. PubMed ID: 14663175
    [No Abstract] [Full Text] [Related]

  • 2. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
    Aydinok Y, Nisli G, Kavakli K.
    Br J Haematol; 1999 Jul; 106(1):252-3. PubMed ID: 10444196
    [No Abstract] [Full Text] [Related]

  • 3. Immune and neural status of thalassemic patients receiving deferiprone or combined deferiprone and deferoxamine chelation treatment.
    Tourkantoni N, Athanassiou-Metaxa M, Zafiriou D, Tzimouli V, Economou M, Taparkou A, Perifanis V, Kanakoudi-Tsakalidou F.
    Hemoglobin; 2008 Jul; 32(1-2):35-40. PubMed ID: 18274981
    [Abstract] [Full Text] [Related]

  • 4. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    St Pierre TG.
    Lancet; 2003 Jan 11; 361(9352):182; author reply 183-4. PubMed ID: 12531617
    [No Abstract] [Full Text] [Related]

  • 5. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C.
    Haematologica; 2003 Dec 11; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract] [Full Text] [Related]

  • 6. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
    Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A.
    Br J Haematol; 2003 Apr 11; 121(1):187-9. PubMed ID: 12670352
    [Abstract] [Full Text] [Related]

  • 7. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
    Loebstein R, Dalal I, Nisbet-Brown E, Berkovitch M, Meydan N, Andrews D, Loubser MD, Koren G, Roifman CM, Olivieri NF.
    Br J Haematol; 1997 Sep 11; 98(3):597-600. PubMed ID: 9332313
    [Abstract] [Full Text] [Related]

  • 8. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.
    Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, Angastiniotis M.
    Haematologica; 2009 Dec 11; 94(12):1777-8. PubMed ID: 19815834
    [No Abstract] [Full Text] [Related]

  • 9. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES, Karasmanis K, Perifanis V, Vlachaki E, Tziomalos K, Economou M.
    Hemoglobin; 2014 Dec 11; 38(2):111-4. PubMed ID: 24351163
    [Abstract] [Full Text] [Related]

  • 10. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Kontoghiorghes GJ, Kolnagou A.
    Lancet; 2003 Jan 11; 361(9352):184. PubMed ID: 12531621
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Hemoglobin; 2011 Jan 11; 35(3):206-16. PubMed ID: 21599433
    [Abstract] [Full Text] [Related]

  • 14. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessì C, Leoni G, Muroni PP, Galanello R.
    Haematologica; 2005 Oct 11; 90(10):1309-14. PubMed ID: 16219566
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Brittenham GM, Nathan DG, Olivieri NF, Pippard MJ, Weatherall DJ.
    Lancet; 2003 Jan 11; 361(9352):183; author reply 183-4. PubMed ID: 12531619
    [No Abstract] [Full Text] [Related]

  • 17. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Jan 11; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 18. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
    Kidson-Gerber G, Lindeman R.
    Br J Haematol; 2008 Aug 11; 142(4):679-80. PubMed ID: 18537970
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Loukopoulos D.
    Haematologica; 2005 Oct 11; 90(10):1304-5. PubMed ID: 16219564
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.